Increased mortality from breast cancer and inadequate axillary treatment

Breast

Volumn 12, Issue 1, 2003, Pages 36-41

  Kingsmore, D B ^a   Ssemwogerere, A ^a   Hole, D J ^a   Gillis, C R ^a   George, W D ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; MEDICAL RECORD; PRESCRIPTION; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 0037303880     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(02)00213-8     Document Type: Article

References (29)

1. Carter C L, Allen C, Henson D. Relation of tumour size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-187.
2. Fisher B, Bauer M, Wickerham D L, Redmund C K, Fisher E R. Relation of number of positive lymph nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer 1983; 52:1551-1557.
3. Veronesi U, Rilke F, Luini A, Sacchini V et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer 1987; 59(4): 682-687.
4. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchini V, Rilke F. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 1990; 16(2): 127-133.
5. Zurrida S, Morabito A, Galimberti V, Luini A, Greco M et al. Importance of the level of axillary involvement in relation to traditional variables in the prognosis of breast cancer. Int J Oncol 1999; 15(3): 475-480.
6. Bonadonna G, Brusamolino E, Valagussa P, Veronessi U. Adjuvant study with combination chemotherapy in operable breast cancer. Proc Am Assoc Cancer Res Am Soc Clin Oncol 1975; 16: 1135a.
7. Recht A, Houlihan M J. Axillary lymph nodes and breast cancer: a review. Cancer 1995; 76: 1491-1512.
8. Hayworth J, Caleffi M. The significance of local control in the primary treatment of breast cancer. Arch Surg 1987; 122: 1244-1247.
9. O'Dwyer P J. Axillary dissection in primary breast cancer. BMJ 1991; 302: 360-361.
10. Fentiman I S, Mansel R E. The axilla: not a no-go zone. Lancet 1991; 337: 221-223.
11. Sacks N D M, Barr L C, Allan S M, Baum M. The role of axillary dissection in operable breast cancer. Breast 1992; 1: 41-49.
12. Sacks N P M, Baum M. Primary management of carcinoma of the breast. Lancet 1993; 342: 1402-1408.
13. Chan H Y, Behen S, Greenall M J. Adequacy of axillary node sampling for evaluation of the axilla and control of axillary disease in breast cancer. Eur J Surg Oncol 1993; 19: 213-214.
14. Davidson T. Why I favour axillary node clearance in the management of breast cancer. Eur J Surg Oncol 1995; 21: 5-7.
15. Greenall M J. Why I favour axillary node sampling in the management of breast cancer. Europ J Surg Oncol 1995; 21: 2-5.
16. Kjaergaard J, Blichert-Toft M, Amdersen J A, Rank F et al. Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer. Br J Surg 1985; 72: 365-367.
17. Steele R J C, Forrest A P M, Gibson T, Stewart H J, Chetty U. The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer. A controlled randomised trial. Br J Surg 1985; 72: 368-369.
18. Blichert-Toft M, Rose C, Andersen J A et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. Monogr Natl Cancer Inst 1992; 11: 19-25.
19. Graverson H P, Blichert-Toft M, Anderson J A, Zedeler K. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988; 14:407-412.
20. Mathieson O, Carl J, Bonderup O, Panduro J. Axillary sampling and the risk of eroneous staging of breast cancer: an analysis of 960 consecutive patients. Acta Oncol 1990; 29: 721-725.
21. Axelsson C K, Mouridsen H T, Zedeler K. Axillary dissection of level I aand II nodes is important in breast cancer classification. Eur J Cancer 1992; 28A: 1415-1418.
22. Kiricuta C I, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992; 69: 2496-2501.
23. Carstairs V, Morris R. Deprivation and Health in Scotland. Aberdeen: Aberdeen University Press, 1988.
24. Cox DR. Regression models and life-tables. J R Star Soc 1972; 34: 187-220.
25. Steele R, Forrest A, Gibson M et al. The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: a controlled randomized trial. Br J Surg 1985; 72: 368-369.
26. Sakorafas G, Tsitou A. Sentinel lymph node biopsy in breast cancer. A review. Am Surg 2000; 66(7): 667-674.
27. Early Breast Cancer Trials Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy; 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
28. Ragaz J, Jackson S M, Nhu Le et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337: 956-962.
29. Overgaard M, Hansen P S, Overgaard J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997; 337:949-955.